1957236-36-0
中文名稱(chēng)
4-[(8-Aminooctyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl
英文名稱(chēng)
4-[(8-Aminooctyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl
CAS
1957236-36-0
分子式
C21H28N4O4
分子量
400.47
MOL 文件
1957236-36-0.mol
1957236-36-0 結(jié)構(gòu)式
基本信息
中文別名
泊馬度胺-氨基泊馬度胺-C8-氨基
英文別名
Pomalidomide-NH2Pomalidomide-C8-NH2
Thalidomide-NH-C8-NH2
4-[(8-Aminooctyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl
1H-Isoindole-1,3(2H)-dione, 4-[(8-aminooctyl)amino]-2-(2,6-dioxo-3-piperidinyl)-
4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
應(yīng)用領(lǐng)域
用途一
Thalidomide-NH-C8-NH2 is a Thalidomide -based cereblon ligand with a linker, which is a useful precursor for synthesis of PROTAC degraders. Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. PROTAC degraders are usually heterobifunctional small molecules consisting of two ligands joined by a linker: one ligand recruits and binds a protein of interest (POI) while the other recruits and binds an E3 ubiquitin ligase. Simultaneous binding of the POI and ligase by the PROTAC induces ubiquitylation of the POI and its subsequent degradation by the ubiquitin–proteasome system (UPS), after which the PROTAC is recycled to target another copy of the POI.